Comparative Pharmacology
Head-to-head clinical analysis: ADDERALL 7 5 versus CONCERTA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADDERALL 7 5 versus CONCERTA.
ADDERALL 7.5 vs CONCERTA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ADDERALL 7.5 is a combination of amphetamine and dextroamphetamine, which are non-catecholamine sympathomimetic amines with CNS stimulant activity. The mechanism of action involves blocking the reuptake of norepinephrine and dopamine into presynaptic neurons, as well as increasing their release into the extraneuronal space. This leads to increased levels of these neurotransmitters in the synaptic cleft, enhancing stimulation of postsynaptic receptors.
Methylphenidate is a central nervous system (CNS) stimulant. It blocks the reuptake of norepinephrine and dopamine into presynaptic neurons, increasing their levels in the synaptic cleft. It also acts as a dopamine agonist by stimulating the release of dopamine from storage sites.
5-20 mg orally 1-3 times daily; immediate-release tablets administered upon awakening and at 4-6 hour intervals as needed; extended-release capsules administered once daily upon awakening; maximum total daily dose 40 mg.
18-72 mg orally once daily in the morning, starting at 18-36 mg/day and titrating in 18 mg increments weekly; maximum 72 mg/day.
None Documented
None Documented
The terminal elimination half-life of amphetamine is approximately 10-13 hours in adults, but can vary based on urinary pH (alkaline urine prolongs half-life up to 20 hours; acidic urine reduces it to 7-8 hours). In children, half-life is slightly shorter (6-8 hours). Clinical context: Steady-state is achieved within 2-3 days.
Terminal elimination half-life of methylphenidate from CONCERTA is approximately 3.5 hours (range 2.5-5.5 hours) in adults; in children, mean half-life is 3-4 hours. The extended-release formulation provides a prolonged clinical effect due to the OROS delivery system, not prolonged half-life.
Renal: approximately 90% of a dose is excreted in urine, with about 30% as unchanged amphetamine and the remainder as metabolites (including deaminated and hydroxylated products). Fecal excretion is negligible (<5%).
Primarily renal (77%-87% as unchanged drug and metabolites); metabolic elimination accounts for 13%-23%, with minor biliary excretion (<2%).
Category C
Category C
CNS Stimulant
CNS Stimulant